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Summary: Coagulation and fibrinolysis activation have been investigated in fifty-eight women with recently de-
tected gynaecological tumours. Twenty-six were benign and 32 malignant: of the last group nine patients had
metastases. A control group consisted of 31 age-matched healthy women. Prothrombin fragment 1 + 2, thrombin-
antithrombin III and D-dimer were measured. The median values of all analytes were significantly higher in the
malignant tumour group, but not in the benign tumour group, as compared to the control group. The group of
patients with a gynaecological tumour and metastases differed from the non-metastasized tumour group in prothrom-
bin fragment 1-1-2, thrombin-antithrombin III and D-dimer. In the non-metastasized malignant tumour group solely
prothrombin fragment 1 + 2 was significantly higher than in the benign tumour group. Coagulation and fibrinolysis
appeared to be activated in the patients with a metastasized gynaecological tumour, fibrinolysis predominating as
can be derived from the elevated D-dimer/thrombin-antithrombin III and D-dimer/prothrombin fragment 1 + 2
ratios. The studied constituents do not enable a differentiation between the benign and malignant processes. How-
ever, as the differences of these values in both malignant tumour groups were significant, this might be used to
trace the existence of metastases in gynaecological tumours. Investigation of these analytes in several specific types
of gynaecological tumours might be clinically relevant.
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Thromboembolism can be demonstrated at autopsy in 50 tion activation was measured by the sensitive clotting
percent of all cancer patients although at most 10 per- turnover products thrombin-antithrombin III complex
cent of these patients actually have significant clinical and prothrombin fragments 1 + 2. The fibrinolytic sys-
signs of thrombosis (9). Episodes of haemorrhage may tern was evaluated by measuring D-dimer.
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Materials and Methods
Pat ien ts
Plasma samples were collected from 58 patients with suspicion
of a benign or malignant gynaecological tumour and subsequent
diagnostic confirmation by histology. On admission to the hospital
no patient showed clinical signs of bleeding or thrombosis.
Twenty-six patients had a benign disease (tab. 1) and 32 patients a
malignancy (tab. 2). In the latter group nine patients had metastases
histologically proven mostly in lymph nodes or peritoneal tissue.
The use of medication was excluded. A reference group consisted
of 31 age-matched ostensibly healthy women.
Samples
Blood samples were drawn between 8.30 and 9.00 a. m. after fast-
ing overnight for 10 h and a resting period of 20 min.
The various constituents were determined in citrated plasma. This
was prepared by centrifugation of a mixture of nine volumes
freshly drawn blood with one volume trisodium citrate (0.11 mol/1)
during 30 min (1600 g) at 25 °C. The plasma was stored at -70 °C
in plastic tubes and thawed at 37 °C for 5 min before batch analy-
sis.
Methods
The prothrombin fragment 1 -I- 2 test was determined with an
ELISA test kit (Behring Corporation, Marburg, Germany). For the
thrombin-antithrombin III determination an ELISA test kit was
used (Behring, Marburg, Germany). The fibrin degradation pro-
ducts were measured by means of the D-dimer test of Boehringer-
Mannheim (Mannheim, Germany). The D-dimer/thrombin-
antithrombin III and the D-dimer/prothrombin fragment 1 + 2 ratio
were calculated on molar basis as arbitrary measures of the fibri-
nolysis/coagulation balance.
The Mann-Whitney U test and the x2-test, where appropriate, were
used for statistical analysis.
Results
In table 1 the diagnoses of the patients with a benign
disease are given. Ovarian cysts occur most in this
group.
Table 2 shows the various tumour types in the patients
with a malignancy. Most of the patients appeared to have
a cervix or an ovarian carcinoma. Metastases were espe-
cially present in the ovarian carcinoma group.
In table 3 a comparison of the benign tumour group,
the total malignant and an age-matched control group is
given. Except for the age, all of the test results showed
Tab. 2 Diagnoses and metastasis status of the malignant tumour
group.
Malignant
tumour
type
Carcinoma cervicis
Ovarian carcinoma
Endometrium carcinoma
Carcinoma of vulva
Leiomyosarcoma uteri
Sarcoma uteri
All
patients
12
10
6
2
1
1
Patients
without
metastases
ι 11
3
6
2
1
0
Patients
with
metastases
1
7
0
0
0
1
a non-Gaussian distribution, and the results are pre-
sented as median values and interquartile ranges. The
group with a benign gynaecological tumour showed sta-
tistically significant higher median values of D-dimer/
thrombin-antithrombin III ratio in comparison with the
age-matched control group. Comparing the malignant
tumour group and the age-matched control group, statis-
tically significantly increased median values were found
for prothrombin fragment 1 + 2, D-dimer and D-dimer/
thrombin-antithrombin III ratio.
In table 4 patients of the malignant group with and with-
out metastases are compared with the benign tumour
group. The values of prothrombin fragment 1+2,
thrombin-antithrombin III, D-dimer, D-dimer/thrombin^
antithrombin III ratio and D-dimer/prothrombin frag-
ment 1 + 2 ratio were significantly increased in the
group with metastases.
Table 5 gives the percentages of decreased and increased
values of the various coagulation and fibrinolysis
constituents in the three patient groups based on the lab-
oratory reference ranges.
Between the benign and the non-metastatic tumour
group significantly different proportions of increased
values were found for prothrombin fragment 1 + 2 and
for D-dimer. The percentages of increased values be-
tween the non-metastatic and metastatic tumour groups
were significantly different for thrombin-antithrombin
III and D-dimer.
Tab. 1 Diagnoses of the benign tumour group.
Benign tumour type Patients
Ovarian/adnex cyst
Ovarian fibroma
Ovarian cyst and myoma uteri
Endometrioma
Myoma uteri
Cyst of unknown origin
15
3
2
2
2
2
Discussion
The patients with a benign gynaecological tumour did
not differ significantly in comparison with the control
group with the exception of the D-dimer/thrombin-
antithrombin ratio. The malignant tumour group how-
ever, showed, compared to the control group, signifi-
cant differences for all measured quantities. Subdivi-
sion of the malignant tumour, group in a group with
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and a group without metastases revealed that the devi- The results reflect a substantial activation of blood coag-
ations in the total malignant tumour group were ulation (prothrombin fragment 1 + 2, thrombin-
mainly due to the patients with metastases. antithrombin III) with reactive fibrinolysis (D-dimer).
Tab. 3 Comparison of the
Number
Age
Prothrombin fragment 1 +
(nmol/1)
Thrombin-antithrombin III
(μ§/0
D-dimer
(μ§/1)
D-dimer/thrombin-
anti thrombin III ratio
D-di mer/prothrombi n
fragment 1 + 2 ratio
Tab. 4 Comparison of the
tumour group.
Number
Age
Prothrombin fragment 1 +
(nmol/1)
Thrombin-antithrombin III
(Mg/l)
D-dimer
(μ§/1)
D-dimer/thrombin-
antithrombin III ratio
D-dimer/prothrombin
fragment 1 4 - 2 ratio
benign and malignant tumour groups with an age-matched control group.
Patients
with benign
gynaecological
tumour
(01)
Median
(25-75
percentiles)
26
53
(46-65)
2 1.00
(0.86-1.50)
2.5
(1.8-3.9)
340
(220-580)
77.3
(66.6-156.2)
1.6
(1.3-4.2)
malignant tumour groups
Patients
with benign
gynaecological
tumour
(Gl)
Median
(25-75
percentiles)
26
53
(45-65)
2 1.00
(0.86-1.50)
2.5
(1.8-3.9)
340
(220-580)
77.3
(66.6-156.2)
1.6
(1.3-4.2)
Patients
with malignant
gynaecological
tumour
(02)
Median
(25-75
percentiles)
32
57
(48-68)
1.50
(1.23-1.95)
3.3
(2.4-8.3)
570
(300-2138)
108.8
(76.0-199.8)
2.3
(1.6-6.7)
with and without
Patients
with malignant
gynaecologcial
tumour
without
metastases
(G2)
Median
(25-75
percentiles)
23
60
(45-70)
1.35
(1.20-1.70)
2.6
(2.0-3.6)
420
(270-680)
84.5
(71.2-125.8)
1.8
(1.4-2.5)
Age Significance
matched p- value
control
group Gl vs G2 Gl vs G3
(G3)
Median
(25-75
percentiles)
31 - -
51 n. s. n. s.
(49-54)
1.10 0.001 n.s.
(0.84-1.35)
2.3 0.007 n. s.
(2.0-3.2)
240 0.003 n.s.
(200-360)
66.1 n.s. 0.047
(37.5-78.8)
1.4 n.s. n.s.
(1.2-2.1) (0.058)
metastases, and the benign
Patients Significance
with malignant p- value
gynaecological
tumour Gl vs G2 Gl vs G3
and metastases
(G3)
Median
(25-75
percentiles)
~ 9 _
54 n.s. n.s.
(49-65)
2.00 <0.02 0.002
(1.85-2.70)
8.5 n.s. <0.000l
(6.4-10.0)
5000 n.s. <0.0001
(1375-6000)
236.7 n. s. 0.003
(160.2-348.4)
7.8 n.s. 0.00005
(6.1-13.1)
G2 vs G3
-
n.s.
0.001
0.03
0.0001
0.0003
0.003
G2 vs G3
-
n.s.
0.03
0.002
0.0002
0.003
0.0002
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Tab. 5 Percentage of decreased and increased values of various ') p = 0.001; 2) p = 0.001; 3) p = 0.026; 4)j> = 0.045;
coagulation and fibrinolysis constituents based on laboratory refer- 5) p = 0.002; 6) p = 0.0005; 7) p = 0.0034
ence ranges. The significant values are indicated (x2-test):
Patients
with benign
gynaecological
tumour
(Gl)
Patients
with malignant
gynaecological tumour
without metastases
(Gl)
Patients
with malignant
gynaecological tumour
and metastases · r
(G2)
Laboratory
reference
range
Decreased Increased
values values
Decreased Increased
values values
Decreased Increased
values values
Prothrombin
fragment 1 + 2
Thrombin-
antithrombin III
D-dimer
0
0
0
44.41),2)
18.53)
33.34),5)
0
0
0
87.01)
21.76)
43.54),7)
0
0
0
88.92)
88.93),6)
1005),7)
0.44- 1.11 nmol/I
1.0 - 4.1 g/l
0 -450 g/l
This phenomenon has also been reported in a number
of other cancer types (14—16). The elevated thrombin-
antithrombin HI levels are consistent with an earlier
study on this topic, in which thrombin-antithrombin III
was considered a marker of malignant gynaecological
disease (17). In general, an explanation for the activation
of blood coagulation in tumours is thought to be a direct
interaction of the coagulation factors with tumour cells
(18, 19) or an indirect production of cytokines (20). The
evidence for both of these etiologies are however based
on immunohistological investigations. An alternative,
well-documented explanation is the evidence for the
production of "cancer procoagulants", which have been
shown to be produced by a large number of cell lines
tested (21).
We calculated the D-dimer/thrombin-antithrombin III
ratio and the D-dimer/prothrombin fragment 1 + 2 ratio
as arbitrary measures for the balance of the fibrinolysis/
coagulation system. Both ratios were increased in favour
of fibrinolysis, being the highest in patients with metas-
tases. The D-dimer/prothrombin fragment 1 + 2 ratio
showed a more pronounced increase than that of D-di-
mer/thrombin-antithrombin III, probably because pro-
thrombin fragment 1 + 2 and thrombin-antithrombin III
differ in production and elimination rates. Fibrinolysis
seems to dominate over the coagulation system, there-
with possibly preventing thrombotic events. Neverthe-
less, when the quantities of fibrinolysis and coagulation
are enhanced the risk for such an event may be increased
(1-3,22-24).
In conclusion, it is not possible to differentiate be-
tween a benign and a malignant process on the basis
of the constituents studied. The haemostasis quantities
seem, however, to give an indication of the existence
of metastases in patients suspected of malignant gyn-
aecological tumours, although we are aware that the
studied patient groups are rather heterogeneous. There-
fore a follow-up study is ongoing focussing on the
more frequent gynaecological cancer types e.g. ovar-
ian cancer and cervix cancer. Moreover, more research
will be necessary to evaluate the clinical impact of the
elevated level of the fibrinolysis/coagulation balance in
patients with the mentioned gynaecological cancer
types.
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